Equity Overview
Price & Market Data
Price: $0.52
Daily Change: +$0.0628 / 12.07%
Range: $0.46 - $0.58
Market Cap: $27,110,394
Volume: 2,418,660
Performance Metrics
1 Week: 38.97%
1 Month: 20.04%
3 Months: 3.98%
6 Months: 125.1%
1 Year: -30.59%
YTD: -43.30%
Company Details
Employees: 13
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.